CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.
Johnson M, El-Khoueiry A, Hafez N, Lakhani N, Mamdani H, Rodon Ahnert J, Sanborn R, Ho T, Li R, Waldes J, Spira A. CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. Journal Of Clinical Oncology 2020, 38: 3502-3502. DOI: 10.1200/jco.2020.38.15_suppl.3502.Peer-Reviewed Original ResearchTreatment-related AEsAntibody-drug conjugatesHuman studiesCommon treatment-related AEsTumor modelObserved safety profileInfusion-related reactionsPK/PD analysisAdvanced solid tumorsAnti-tumor activityXenograft tumor modelMedian molar ratiosMultiple xenograft tumor modelsTumor-associated proteasesECOG 0Dose cohortsStable diseasePartial responsePhase 1/2Systemic therapyAdvanced cancerDose escalationSafety profileGrade 3Ocular melanoma